Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B

Open to people ages 18 years and up

• Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
• Adult males and non-pregnant, non-lactating females
• Documented evidence of chronic HBV infection
• Hepatitis e antigen (HBeAg)-negative, chronic hepatitis B with all of the following:
• HBeAg-negative and hepatitis B e antibody (HBeAb) positive at screening

• Screening HBV DNA ≥ 2 x 10⁴ IU/mL

• Screening serum alanine aminotransferase (ALT) level > 60 U/L (males) or > 38 U/L (females) and ≤ 10 x the upper limit of the normal range (ULN)
• Treatment-naive participants (defined as < 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue), OR treatment-experienced participants (defined as participants meeting all entry criteria [including HBV DNA and serum ALT criteria] and with ≥ 12 weeks of previous treatment with any nucleoside or nucleotide analogue)
• Previous treatment with interferon (pegylated or non pegylated) must have ended at least 6 months prior to the baseline visit.
• Adequate renal function
• Normal ECG

• Females who are breastfeeding
• Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study
• Co-infection with hepatitis C virus, HIV, or hepatitis D virus
• Evidence of hepatocellular carcinoma
• Any history of, or current evidence of, clinical hepatic decompensation
• Abnormal hematological and biochemical parameters, including aspartate aminotransferase (AST) > 10 x ULN
• Received solid organ or bone marrow transplant
• History of malignancy within the past 5 years, with the exception of specific cancers that are cured by surgical resection; individuals under evaluation for possible malignancy are not eligible
• Currently receiving therapy with immunomodulators (eg, corticosteroids), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion
• Individuals receiving ongoing therapy with drugs not to be used with tenofovir alafenamide or tenofovir disoproxil fumarate or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients
• Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance
• Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements

Note: Other protocol defined Inclusion/Exclusion criteria may apply.